{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:14:00Z","timestamp":1791335640412,"version":"4.3.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ebiom.2020.103160","type":"journal-article","created":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T18:31:52Z","timestamp":1611772312000},"page":"103160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response"],"prefix":"10.1016","volume":"64","author":[{"given":"Floris","family":"Dammeijer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4447-0149","authenticated-orcid":false,"given":"Cornedine J.","family":"De Gooijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy","family":"van Gulijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Lukkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Klaase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lysanne A.","family":"Lievense","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Waasdorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merel","family":"Jebbink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerben P.","family":"Bootsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos A.","family":"Stigt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonne","family":"Biesma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaretha E.H.","family":"Kaijen-Lambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Mankor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heleen","family":"Vroman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Baas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Van der Noort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobus A.","family":"Burgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim G.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"(Popat S.","key":"10.1016\/j.ebiom.2020.103160_bib0001","article-title":"A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): results from the European Thoracic Oncology Platform (ETOP 9- 15) PROMISE-meso trial","volume":"30","author":"Popat","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ebiom.2020.103160_bib0002","first-page":"e161","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"19","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ebiom.2020.103160_bib0003","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S1470-2045(18)30100-1","article-title":"Novel therapies for malignant pleural mesothelioma","volume":"19","author":"Scherpereel","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ebiom.2020.103160_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30362-3","article-title":"Switch maintenance gemcitabine after first line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated randomised open label phase 2 trial","author":"de Gooijer","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.ebiom.2020.103160_bib0005","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological effects of conventional chemotherapy and targeted anticancer agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.ebiom.2020.103160_bib0006","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1158\/1078-0432.CCR-17-2522","article-title":"Autologous dendritic cells pulsed with allogeneic tumor cell lysate in mesothelioma: from mouse to human","volume":"24","author":"Aerts","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ebiom.2020.103160_bib0007","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2010.223","article-title":"Immune parameters affecting the efficacy of chemotherapeutic regimens","volume":"8","author":"Zitvogel","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"issue":"18","key":"10.1016\/j.ebiom.2020.103160_bib0008","doi-asserted-by":"crossref","first-page":"6713","DOI":"10.1158\/1078-0432.CCR-05-0883","article-title":"Gemcitabine selectively eliminates splenic Gr-1+\/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity","volume":"11","author":"Suzuki","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ebiom.2020.103160_bib0009","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12967-016-1037-z","article-title":"Gemcitabine reduces MDSCs, tregs and TGFbeta-1 while restoring the teff\/treg ratio in patients with pancreatic cancer","volume":"14","author":"Eriksson","year":"2016","journal-title":"J Transl Med"},{"issue":"3","key":"10.1016\/j.ebiom.2020.103160_bib0010","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s12094-013-1079-0","article-title":"Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer","volume":"16","author":"Homma","year":"2014","journal-title":"Clin Transl Oncol"},{"issue":"6","key":"10.1016\/j.ebiom.2020.103160_bib0011","doi-asserted-by":"crossref","first-page":"880","DOI":"10.4161\/cbt.6.6.4090","article-title":"Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects","volume":"6","author":"Suzuki","year":"2007","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"10.1016\/j.ebiom.2020.103160_bib0012","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ebiom.2020.103160_bib0013","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00001648-199001000-00010","article-title":"No adjustments are needed for multiple comparisons","volume":"1","author":"Rothman","year":"1990","journal-title":"Epidemiology"},{"issue":"6","key":"10.1016\/j.ebiom.2020.103160_bib0014","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.immuni.2009.03.019","article-title":"Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor","volume":"30","author":"Miyara","year":"2009","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.ebiom.2020.103160_bib0015","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaf8943","article-title":"Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients","volume":"1","author":"Condamine","year":"2016","journal-title":"Sci Immunol"},{"issue":"12","key":"10.1016\/j.ebiom.2020.103160_bib0016","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/jjco\/hyp112","article-title":"Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer","volume":"39","author":"Soeda","year":"2009","journal-title":"Jpn J Clin Oncol"},{"issue":"16","key":"10.1016\/j.ebiom.2020.103160_bib0017","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1182\/blood-2011-11-392951","article-title":"Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity","volume":"119","author":"Ndhlovu","year":"2012","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.ebiom.2020.103160_bib0018","doi-asserted-by":"crossref","first-page":"6345","DOI":"10.1158\/1078-0432.CCR-18-1231","article-title":"Gemcitabine synergizes with immune checkpoint inhibitors and overcomes resistance in a preclinical model and mesothelioma patients","volume":"24","author":"Tallon de Lara","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ebiom.2020.103160_bib0019","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1053\/j.gastro.2016.05.004","article-title":"Administration of gemcitabine after pancreatic tumor resection in mice induces an antitumor immune response mediated by natural killer cells","volume":"151","author":"Gurlevik","year":"2016","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.ebiom.2020.103160_bib0020","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1038\/s41598-018-38190-2","article-title":"In vitro culture with gemcitabine augments death receptor and NKG2D ligand expression on tumour cells","volume":"9","author":"Gravett","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ebiom.2020.103160_bib0021","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/eji.201444722","article-title":"Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy","volume":"45","author":"McDonnell","year":"2015","journal-title":"Eur J Immunol"},{"issue":"10","key":"10.1016\/j.ebiom.2020.103160_bib0022","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.4049\/jimmunol.170.10.4905","article-title":"Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells","volume":"170","author":"Nowak","year":"2003","journal-title":"J Immunol (Baltimore, Md : 1950)"},{"issue":"1","key":"10.1016\/j.ebiom.2020.103160_bib0023","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/sj.bjc.6605465","article-title":"Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses","volume":"102","author":"Liu","year":"2010","journal-title":"Br J Cancer"},{"issue":"19","key":"10.1016\/j.ebiom.2020.103160_bib0024","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1073\/pnas.1705327114","article-title":"Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1\u2013targeted therapy in lung cancer patients","volume":"114","author":"Kamphorst","year":"2017","journal-title":"Proc Natl Acad Sci"},{"issue":"7652","key":"10.1016\/j.ebiom.2020.103160_bib0025","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396420305363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396420305363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:02:57Z","timestamp":1762455777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396420305363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":25,"alternative-id":["S2352396420305363"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2020.103160","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2020.103160","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103160"}}